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Background: Aortic stenosis (AS) shares several similarities with atherosclerosis. Recent reports showed
that B cells are implicated in atherosclerosis progression through macrophage–B cells bidirectional
interaction.
We aimed to study the in loco presence of B cells within aortic valves and to determine itsmodulators.
Methods: Thirty-seven patients with severe AS were studied. Immunohistochemistry was performed on
valve leaﬂets using antibodies against CD20, B cell-activating factor of the tumor necrosis factor family
receptor (BAFF-R) and CD68. Plasma inﬂammatory markers were also determined.
Results: The B cells were detected within aortic leaﬂets from 5 to 31/mm2 (17.9  11.6/mm2). Double-
staining showed that 27  13.5% of B cells express BAFF-R. There were positive correlations between the
number of B cells and macrophages (r = 0.45, p = 0.018), and between macrophages and B cell-associated
BAFF-R expression (r = 0.66, p = 0.002). The number of B cells was associated with the valve calciﬁcation
(r = 0.41, p = 0.039), andwith themaximum transvalvular gradient (r = 0.63, p = 0.02). The BAFF-R expression
was positively correlated with maximum transvalvular gradient (r = 0.39, p = 0.031) and negatively with
aortic valve area (r = 0.41, p = 0.048). There were no correlations between the number of B cells and plasma
markers.
Conclusions: It might be hypothesized that, like in atherosclerosis, increasing number of B cells within
aortic valves may accelerate inﬂammation and thus potentiate the progression of AS.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.Introduction
Calciﬁc aortic valve stenosis (AS) is the most common heart
valve disease in the Western world being present in 2–3% of the
population by the age of 65 years [1]. On average, 50 000 aortic
valve replacements every year are performed both in Europe and
the USA [2]. Several lines of evidence indicating that AS shares
some clinical and histological similarities with atherosclerosis [3]
have led us to the concept that mechanisms involved in
atherosclerosis development and progression could operate in
AS. Recent data showed the important role of B cell activation in
the formation of atherosclerotic lesions, particularly by driving* Corresponding author at: Institute of Cardiology, Jagiellonian University School
of Medicine, 80 Pradnicka St., 31-202 Krakow, Poland. Tel.: +48 12 6143143;
fax: +48 12 6143143.
E-mail address: j.natorska@szpitaljp2.krakow.pl (J. Natorska).
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0914-5087/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightspro-atherogenic immune response through granulocyte macro-
phage colony-stimulating factor [4] and limited production of
atheroprotective interleukin-17 [5]. It is thought that B cells may
drive T cell activation toward enhanced pro-atherogenic helper T
cell (Th)1 response to modiﬁed autoantigens of oxidized low-
density lipoproteins (oxLDL), which are presented by activated
macrophages or dendritic cells and the depletion of mature B cells
using CD20 antibodies reduced the development of atherosclerosis
in mouse models of the disease [5]. Since it was shown that in AS
the valvular degeneration is preceded by endothelial damage,
accumulation of oxLDL, inﬂammatory cell inﬁltration, and foam
cell formation, which in turn undergo apoptosis [1,6], mechanisms
similar to that of atherosclerosis could also operate in AS. Little is
known about the role of B cells as a part of the inﬁltrating cell
population within stenotic valves. This might be because B cells
have classically been considered to exert long-range effects,mostly
via activation of secondary organs. However, some studies
described the role of local B cell inﬁltrates in tissue ﬁbrosis,reserved.
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several forms of inﬂammatory kidney diseases, including
glomerulonephritis [8], lupus nephritis, and renal transplant
rejection [9–11]. Intrarenal B cells have been shown to have a
much broader role in renal inﬂammation than the production of
pathogenic antibodies, and they also are functioning as antigen-
presenting cells, regulators of T cells, macrophages, dendritic
cells, and are involved in the formation of local lymphatic
expansion [12].
Moreover, previous studies showed the importance of macro-
phage–B cells bidirectional interaction for B cell activation and
efﬁcient antigen presentation, in a T cell-independent manner via
Toll-like receptors [13], or throughmacrophage-derived cytokines,
such as B cell-activating factor of the tumor necrosis factor family
(BAFF, also termed B-lymphocyte stimulator) [14] and/or cell–cell
contact through the interaction of immunoglobulins with macro-
phage receptor FcgR [15]. BAFF on binding to its receptors BAFF-R
exerts strong stimulation on B cells, promoting B cell survival and
maturation [16–20]. Increased serum and/or plasma levels of BAFF
have been documented in several human autoimmune diseases
[17,18] and in kidney diseases [19].
In patients with severe AS, the occasional presence of B cells
within aortic valves was reported previously by Edep et al. [20]. On
the other hand, Steiner et al. [21] have shown an abundance of B
cells within the valves from patient with severe AS (ranging from
30 to 100 cells per ﬁeld). However, the role of B cells and their
bidirectional interactions with other leukocytes in AS remain
largely unknown. It is also unclear whether isolated AS in patients
without stenosis in coronary, carotid, or peripheral arteries is also
associated with increased number of B cells.
The aim of this studywas to investigate the in loco presence and
activation of B cells within aortic valve leaﬂets in patients with AS
free of signiﬁcant atherosclerotic vascular disease.
Methods
Patients
Aortic valves and blood samples were obtained from
37 patients (16 women, 21 men, mean transvalvular gradient
41.23  12.54 mmHg, mean age 59.7  [5_TD$DIFF]7.1 years) with dominant AS,
deﬁned as mean transvalvular gradient >40 mmHg on transthoracic
echocardiography. Patients undergoing aortic valve replacement for
severe ASwere recruited at the Department of Cardiovascular Surgery
and Transplantology at John Paul II Hospital in Krakow.
The exclusion criteria were: rheumatic AS, acute infection,
diabetes, Valsalva sinus aneurysm, angiographically documented
coronary AS (>20% diameter), carotid artery stenosis >30%,
peripheral artery disease (with intermittent claudication or ankle
brachial index <0.9), known cancer, autoimmune disorders,
endocarditis, previous cardiac surgery, a history of myocardial
infarction, stroke, venous thromboembolism, pregnancy, and lack
of written consent. Patients who required additional surgical
intervention or had other heart defects were ineligible.
Diabetes mellitus was deﬁned as a previous diagnosis of
diabetes, or at least two random fasting glucose levels of
>7 mmol/l. Arterial hypertension was diagnosed based on a
history of hypertension (blood pressure >140/90 mmHg) or
preadmission antihypertensive treatment. Hyperlipidemia was
diagnosed based on total cholesterol of 5.2 mmol/l or more, or
statin therapy.
Patients gave their informed consent and the University
Bioethical Committee approved the study.
Five aortic valves from age-matched apparently healthy
subjects, obtained at autopsy, without morphological valvular or
other cardiac disorders served as negative controls.Echocardiography
Transthoracic echocardiography was performed in each patient
using a GE Vivid 7 ultrasound machine (GE Healthcare, Chalfont St
Giles, UK) prior to surgery. Measurements were performed using
conventional techniques in accordance with the current European
Society of Cardiology (ESC) guidelines [22]. The aortic valve area
(AVA) was calculated using the standard continuity equation. The
transvalvular gradient was measured by Doppler echocardiogra-
phy using the modiﬁed Bernoulli equation.
Laboratory tests
Fasting venous blood was drawn from patients 24 h before
surgery between 07.00 h and 09.00 h. Citrated blood samples (9:1
of 0.106 M sodium citrate) were centrifuged at 2500  g at 20 8C
for 10 min. Lipid proﬁle, glucose, and creatinine were assayed by
routine laboratory techniques. High-sensitivity C-reactive protein
(CRP) was determined using immunoturbidimetry (Roche Diag-
nostics, Mannheim, Germany). Fibrinogen was measured by the
von Clauss method (Instrumentation Laboratory, Bedford, MA,
USA).
Immunostaining
After a gross examination and description, aortic valve leaﬂets
were decalciﬁed, cryopreserved, and cryosectioned as described
before [23]. Sections taken transversely from the mid of the leaﬂet
and from commissural areas were stored at 20 8C until
immunostaining. At least one tissue sample was stained with
hematoxylin–eosin to visualize inﬂammatory cells and neovessels.
We performed indirect immunohistochemistry using mono-
clonal antibodies CD20, CD68 (Dako, Glostrup, Denmark), and
BAFF-R (Abcam, Cambridge, UK). Endogenous peroxidase activity
was inhibited by immersing the sections in 3% hydrogen peroxide.
Finally, the sections were incubated with the corresponding
secondary antibodies conjugated with ﬂuorochrome (R&D Sys-
tems, Minneapolis, MN, USA) or by the avidin–biotin complex
immunoperoxidase (Dako). Double-immunoﬂuorescence for CD20
and BAFF-R-positive cells was also performed (n = 29). A negative
control (without primary antibody incubation) was included
routinely. Decalciﬁcation had no effect on tissue antigenicity, as
determined by investigations on undecalciﬁed valve sections.
The calciﬁcation degree was analyzed subjectively, semi-
quantitatively according to the following scoring system: 0; 1;
2: absence; isolated calcium deposits (10–20% of total valve area);
abundant calcium deposits (>20% of total valve area), respectively.
The numbers of CD20-, CD-68-, and BAFF-R-positive cells were
counted at 40 magniﬁcation, using Motic Images Plus 2.0 soft-
ware (Motic, Hong Kong), throughout the entire section in 9 slides
per valve (3 per each leaﬂet) and expressed as the cell number per
square millimeter. Three images were acquired from a randomly
selected location.
Statistical analysis
Values are expressed as mean (SD) or median (interquartile
range) or otherwise stated. The Kolmogorov–Smirnov test was
used to assess conformity with a normal distribution. Pairwise
comparisons were made using Tukey’s test for continuous
variables. The Mann–Whitney U test was used to compare non-
normally distributed variables between two groups. To assess
linear dependence between variables, the Pearson’s correlation
coefﬁcient for normally distributed or Spearman’s rank correlation
coefﬁcient for non-normally distributed variables was calculated.
A value of p < 0.05 was considered statistically signiﬁcant. Data
Table 1
Characteristics of aortic stenosis patients (n=37).
Male, n (%) 21 (57)
Age (years) 59.77.1
Body mass index (kg/m2) 28.67.4
Risk factors
Hypertension, n (%) 24 (65)
Hypercholesterolemia, n (%) 12 (32)
Current smoking, n (%) 5 (14)
Echocardiography
Maximum gradient (mmHg) 68.516.7
Mean gradient (mmHg) 41.2312.54
LVEF (%) 57.788.42
Calciﬁed valves, n (%) 37 (100)
AVA (cm2) 0.93 0.4
Laboratory parameters
Glucose (mmol/l) 5.272.83
Creatinine (mmol/l) 81 [59–127]
Total cholesterol (mmol/l) 4.592.1
HDL cholesterol (mmol/l) 1.20 0.19
LDL cholesterol (mmol/l) 2.631.1
TG (mmol/l) 1.821.13
Fibrinogen (g/l) 4.811.93
hsCRP (mg/l) 6.56 [1.34–18.26]
Data are mean (SD), median or number (percentage).
LVEF, left ventricular ejection fraction; AVA, aortic valve area; HDL, high-
density lipoprotein; LDL, low-density lipoprotein; TG, triglycerides; hsCRP,
high-sensitive C-reactive protein.
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Results
The demographic, clinical echocardiographic, and laboratory
characteristics of the AS patients are summarized in Table 1.
In all 37 (100%) cases, the aortic valve cusps were calciﬁed with
large calcium deposits, mostly in the ﬁbrosa and subendothelial
layer predominantly from the aortic side.
Thirty-ﬁve (95%) aortic valves were characterized by coloca-
lization of inﬂammatory cell inﬁltrates close to the calcium
deposits. Analysis of inﬂammatory inﬁltrates within stenotic
valves showed mostly macrophages (CD68 positive cells) with
their maximum concentration of 64  24 cells per mm2. The
majority of macrophages were located close to the calcium deposits
and areas of vascularization; however, these cells were also present
sparsely in other areas of the leaﬂets.
The immunoﬂuorescent study showed that in leaﬂets from
control aortic valves no B cells were present (Fig. 1A), whereas the
presence of B cells was revealed within all examined valve leaﬂets
from AS patients (Fig. 1B and C). The number of B cells ranged from
5 to 31/mm2 (17.9  11.6 cells per mm2). B cells were associated
with neovascularized areas and dispersed exclusively within the
subendothelium and ﬁbrosa predominantly from the aortic side of[(Fig._1)TD$FIG]
Fig. 1. B cells and B cell-activating factor of the tumor necrosis factor family receptor (BAFF-R) immunostaining within control and stenotic valves. Microphotographs of
immunostaining of B cell-associated CD20 receptors in (A) controls, where no B cells were present, (B) in AS patients where B cells were found,mainly on the aortic side of the
valve leaﬂets (*), stained immunoenzymatically with avidin–biotin complex (brown) and counterstained with hematoxylin, to show other immunonegative cells (dark blue)
or (C) using immunoﬂuorescence stainingwith phycoerythrin (red). (D) Double-labeled immunostaining of CD20 (stainedwith phycoerythrin; red) and BAFF-R (stainedwith
ﬂuoroisothiocianate; green). Co-localized areas of each factor are stained yellow and orange (combination of red and green); green background – nonspeciﬁc staining of
collagen ﬁbers. Original magniﬁcation 40; inserts – 100[1_TD$DIFF].
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with the degree of valve calciﬁcation (r = 0.41, p = 0.039).
Double-staining showed that 27  13.5% of B cells expressed
receptor BAFF-R (Fig. 1D). There were positive correlations not only
between the numbers of B cells andmacrophages (r = 0.45, p = 0.018),
but also between the number of macrophages and B cell-associated
BAFF-R expression (r = 0.66, p = 0.002) (Fig. 2A and B).
There were positive correlations of both the number of valvular
B cells and B cell-associated BAFF-R expression with echocardio-
graphic parameters describing the severity of AS. The number of B
cells was correlated with maximum (r = 0.63, p = 0.02) transvalv-
ular gradient and tended to correlate with mean transvalvular
gradient (r = 0.41, p = 0.059), and with aortic valve area (r = 0.45,
p = 0.054). Moreover, the BAFF-R expression was positively
correlated with maximum transvalvular gradient (r = 0.39,
p = 0.031) and negatively with AVA (r = 0.41, p = 0.048).
There were no statistically signiﬁcant correlations between B
cell number or BAFF-R expression and plasma CRP, ﬁbrinogen,
glucose, or lipids.
There were no age-, gender-, smoking-, or medication-related
correlations with B cell number or BAFF-R.
Discussion
Our study is the ﬁrst to show that in patients with AS without
documented signiﬁcant atherosclerotic vascular disease, B cells are
not only present within aortic valve leaﬂets, but also they are
activated, as evidenced by their expression of BAFF-R. Moreover,
our ﬁndings indicate that there are potential interactions between
B cells and macrophages which can drive inﬂammatory processes
within AS valves as evidenced by signiﬁcant associations between
[(Fig._2)TD$FIG]
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[2_TD$DIFF] ig. 2. Relations between the numbers of macrophages and (A) valvular B cell
(n = 37); (B) B cell-activating factor of the tumor necrosis factor family receptor
(BAFF-R) positive B cells (n = 29).the number of macrophages and BAFF-R expression intensity.
Importantly, the number of B cells has been shown to be associated
with the severity of AS, suggesting a negative impact of increasing
numbers of B cells on the progression of aortic valve dysfunction,
even in individuals free of clinically overt atherosclerosis. Our
study provides additional evidence for an important, although
poorly deﬁned, role of B cell-mediated immune responses in
various manifestations of vascular diseases including so-called
atherosclerosis-like processes such as AS.
Based on our ﬁndings, it might be speculated that accumulation
of B cells within aortic leaﬂets and their interaction with
macrophages can be implicated in progressive thickening and
calciﬁcation of aortic valves, the more that there was[3_TD$DIFF] a
colocalization of macrophages and activated B cells.
It is known that there are close bidirectional interactions
between inﬂammation and activation of blood coagulation and in
consequence with calciﬁcation of aortic valves [1,24,25,23,26,27];
thus, the presence of B cells might indirectly contribute to AS
progression in part through thrombin-mediated mechanisms. We
have previously shown that in AS patients, tissue factor expressed
by macrophages was colocalized with areas of inﬂammatory cell
inﬁltration [25] and ﬁbrin accumulation within the leaﬂets
[23]. Breyne and co-workers [27] have shown that in calciﬁed
human aortic valves, tissue factor is associated with expression of
a-thrombin, which produces a number of harmful effects
including enhanced cell proliferation [28,29], proinﬂammatory
mechanisms mediated in part by prostaglandins [29,30], chemo-
taxis [31], and angiogenesis [32]. Moreover, the amount of ﬁbrin
and the degree of valve calciﬁcation have been reported to
correlate with the alternatively activated macrophages recruited
to the valve leaﬂets [33]. To what extent increased formation of
thrombin and the subsequent ﬁbrin might be associated with the
presence of activated B cells within the stenotic valves remains to
be established.
On the other hand, there is compelling evidence that elevated
levels of macrophage-derived BAFF protein are associated with
additional defective efferocytosis of apoptotic bodies, resulting from
inﬂammation [33,34]. It is known that apoptosis is enhancedwithin
stenotic valves [35]. Moreover, in AS apoptosis has been shown to
alter endothelial integrity, leading to the increased inﬁltration of
calcium into the deeper layer of the valve tissues [35]. Since
apoptosis-derived cellular degradation products provide the sub-
strates for calcium binding with progressive development of
calciﬁcation in the valve tissue [35], defective efferocytosis might
be involved in AS progression, like it is in atherosclerosis. Based on
our ﬁndings we might speculate that BAFF present within aortic
valves may affect the rate of leaﬂet calciﬁcation.
It might be hypothesized that the accumulation of apoptotic
cell debris due to defective efferocytosis, together with modiﬁed
lipids, might activate critical immuno-inﬂammatory pathways,
drive valve calciﬁcation, and potentiate the progression of AS with
and without concomitant atherosclerotic vascular disease.
Moreover, B cell numbers and activation showed correlations
with echocardiographic parameters, which might indicate that
high pressure gradients in AS patients can increase the inﬂamma-
tory state. However, it is not entirely clear whether originally a
large number of B cells recruited to stenotic valves are not
associated with a large number of neovessels formed in those
valves rather than with disturbed hemodynamic parameters. In
the present study, no impact of B cells on the plasma markers was
found; however, it is not surprising since it is known that stenotic
valves alter hemodynamic conditions with the subsequent
hemostatic abnormalities, which are in part reﬂected rather in a
more marked activation of systemic blood coagulation and
ﬁbrinolysis [36–38] than in enhanced inﬂammation or impaired
homeostasis.
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the concept that chronic inﬂammation plays a pivotal role in the
pathogenesis of AS. Since the depletion of mature B cells using
rituximab, which cross links the CD20 receptor present on all B
cells leading to their depletion [39], as well as BAFF-R deﬁciency
caused by belimumab, which blocks soluble BAFF from binding to
its receptor [40], reduced the development of atherosclerosis in
mice it might be hypothesized that in AS patients therapy with
those drugs could reduce the valvular inﬂammation, limit humoral
response to the oxLDLs within stenotic valves, and thus affect the
rate of the disease progression. It is particularly interesting that
similar B cell depletion strategies are approved as treatments for
cardiovascular diseases and atherosclerosis development in
patients with rheumatoid arthritis and systemic lupus erythema-
tosus [41]. However, regarding the data that the initiation of
pathologic lesions leading to AS is associated with partial
denudation of valve surface endothelium [42], which results in
impaired anticoagulant and anti-aggregatory effects [43] leading
to inﬂammation and ﬁnally calciﬁcation of valve leaﬂets, B cell
depletion therapy could be useful only in subjects with recognized
mild-to-moderate AS probably to limit not to prevent the disease
development.
Several limitations of this study should be acknowledged. First,
the number of the patients enrolled in this study was limited;
however, the presence of B cells was found in 100% of cases, which
allows one to suppose that it is a common phenomenon in stenotic
valves. Second, the present study is focused on patientswith severe
AS, and the rate of progression of the defect in the individual
patients remained unknown. Therefore, changes in B cell activation
in the AS valves over time and the impact of those cells on the AS
progression cannot be evaluated using the current approach and
our ﬁndings cannot be extrapolated to subjectswithmild AS. Third,
BAFF protein expressed by macrophages has not been determined.
However, the activation of BAFF-R occurs exclusively under BAFF
expression. To conﬁrm our observations in humans, an animal
model of AS could be developed, in which the inﬂuence of B cell
activation on disease progression could be corroborated.
Conclusions
We suggest that integration of the knowledge about the
pathophysiology of B cells in AS and their involvement in
inﬂammation, calciﬁcation, and apoptosis processes ongoing
within stenotic valves could contribute to the understanding of
the mechanisms of AS progression and thus to limit the disease
progression.
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